
<?xml version="1.0" encoding="UTF-8"?>
<DataElementsList>
   <DataElement num="1">
      <PUBLICID>2182885</PUBLICID>
      <LONGNAME>Blood Pressure, Diastolic</LONGNAME>
      <PREFERREDNAME>BLD_PRESS_DIASTOLIC</PREFERREDNAME>
      <PREFERREDDEFINITION>Indicating the arterial pressure during the interval between heartbeats.</PREFERREDDEFINITION>
      <VERSION>1.0</VERSION>
      <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
      <CONTEXTNAME>DCP</CONTEXTNAME>
      <CONTEXTVERSION>1.0</CONTEXTVERSION>
      <ORIGIN>FALSE</ORIGIN>
      <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
      <DATAELEMENTCONCEPT>
         <PublicId>2013135</PublicId>
         <PreferredName>BP</PreferredName>
         <PreferredDefinition>Measurement of the pressure of the BLOOD on the ARTERIES and other BLOOD VESSELS._The contraction of the chambers of the heart (especially the ventricles) to drive blood into the aorta and pulmonary artery._Person; a human being.</PreferredDefinition>
         <LongName>Person Blood Pressure Assessment</LongName>
         <Version>1.0</Version>
         <WorkflowStatus>RELEASED</WorkflowStatus>
         <ContextName>CCR</ContextName>
         <ContextVersion>1.0</ContextVersion>
         <ConceptualDomain>
            <PublicId>2008551</PublicId>
            <ContextName>CTEP</ContextName>
            <ContextVersion>1.0</ContextVersion>
            <PreferredName>ASSESS</PreferredName>
            <Version>1.0</Version>
            <LongName>Assessments</LongName>
         </ConceptualDomain>
         <ObjectClass>
            <PublicId>0</PublicId>
            <ContextName>NCIP NCIP</ContextName>
            <ContextVersion>1.0 1.0</ContextVersion>
            <PreferredName>C25190 C54706</PreferredName>
            <Version>1.0 1.0</Version>
            <LongName>Person Blood Pressure</LongName>
            <ConceptDetails>
               <ConceptDetails_ITEM>
                  <PREFERRED_NAME>C25190 C54706</PREFERRED_NAME>
                  <LONG_NAME>Person Blood Pressure</LONG_NAME>
                  <CON_ID>2202486 2552352</CON_ID>
                  <DEFINITION_SOURCE>NCI NCI</DEFINITION_SOURCE>
                  <ORIGIN>NCI Thesaurus NCI Thesaurus</ORIGIN>
                  <EVS_SOURCE>NCI_CONCEPT_CODE NCI_CONCEPT_CODE</EVS_SOURCE>
                  <PRIMARY_FLAG_IND>Yes Yes</PRIMARY_FLAG_IND>
                  <DISPLAY_ORDER>1 0</DISPLAY_ORDER>
               </ConceptDetails_ITEM>
            </ConceptDetails>
         </ObjectClass>
         <Property>
            <PublicId>0</PublicId>
            <ContextName>NCIP</ContextName>
            <ContextVersion>1.0</ContextVersion>
            <PreferredName>C25367</PreferredName>
            <Version>1.0</Version>
            <LongName>Assessment</LongName>
            <ConceptDetails>
               <ConceptDetails_ITEM>
                  <PREFERRED_NAME>C25367</PREFERRED_NAME>
                  <LONG_NAME>Assessment</LONG_NAME>
                  <CON_ID>2203593</CON_ID>
                  <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
                  <ORIGIN>NCI Thesaurus</ORIGIN>
                  <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
                  <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
                  <DISPLAY_ORDER>0</DISPLAY_ORDER>
               </ConceptDetails_ITEM>
            </ConceptDetails>
         </Property>
      </DATAELEMENTCONCEPT>
      <VALUEDOMAIN>
         <PublicId>2182883</PublicId>
         <PreferredName>C25337</PreferredName>
         <PreferredDefinition>Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.</PreferredDefinition>
         <LongName>Blood pressure, Diastolic</LongName>
         <Version>1.0</Version>
         <WorkflowStatus>RELEASED</WorkflowStatus>
         <ContextName>DCP</ContextName>
         <ContextVersion>1.0</ContextVersion>
         <ConceptualDomain>
            <PublicId>2202701</PublicId>
            <ContextName>NCIP</ContextName>
            <ContextVersion>1.0</ContextVersion>
            <PreferredName>C25337</PreferredName>
            <Version>1.0</Version>
            <LongName>Number</LongName>
         </ConceptualDomain>
         <Datatype>NUMBER</Datatype>
         <MaximumLength>8</MaximumLength>
         <Representation>
            <PublicId>2233101</PublicId>
            <ContextName>C25337</ContextName>
            <ContextVersion>1.0</ContextVersion>
            <PreferredName>C25337</PreferredName>
            <Version>1.0</Version>
            <LongName>Number</LongName>
            <ConceptDetails>
               <ConceptDetails_ITEM>
                  <PREFERRED_NAME>C25337</PREFERRED_NAME>
                  <LONG_NAME>Number</LONG_NAME>
                  <CON_ID>2202701</CON_ID>
                  <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
                  <ORIGIN>NCI Thesaurus</ORIGIN>
                  <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
                  <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
                  <DISPLAY_ORDER>0</DISPLAY_ORDER>
               </ConceptDetails_ITEM>
            </ConceptDetails>
         </Representation>
         <PermissibleValues>
            <PermissibleValues_ITEM>
               <VALIDVALUE/>
               <VALUEMEANING/>
               <MEANINGDESCRIPTION/>
               <MEANINGCONCEPTS>FALSE</MEANINGCONCEPTS>
               <VMPUBLICID/>
               <VMVERSION/>
            </PermissibleValues_ITEM>
         </PermissibleValues>
         <ValueDomainConcepts/>
      </VALUEDOMAIN>
      <REFERENCEDOCUMENTSLIST>
         <REFERENCEDOCUMENTSLIST_ITEM>
            <Name>Blood Pressure, Diastolic</Name>
            <DocumentType>Preferred Question Text</DocumentType>
            <DocumentText>Blood Pressure, Diastolic</DocumentText>
            <Language>ENGLISH</Language>
            <DisplayOrder NULL="display-order">TRUE</DisplayOrder>
         </REFERENCEDOCUMENTSLIST_ITEM>
      </REFERENCEDOCUMENTSLIST>
      <CLASSIFICATIONSLIST>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812516 2812017 2812017</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE DISEASE</PreferredName>
               <Version>1.0 2.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Subclinical Neoplastic Lesions Phase II Lung Cancer Phase II Lung Cancer</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812516 2812017 2812017</CsiPublicId>
            <CsiVersion>1.0 2.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812102 2812151 2812245</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Condition DISEASE</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Budesonide Lung Nodules Prostate - Lycopene Phase II Breast Cancer</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812102 2812151 2812245</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812148 2812182 2812625</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Condition Clinical Trial Mgmt Systems</PreferredName>
               <Version>1.0 1.0 1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>SAMe - Hepatitis C cirrhosis Tissue Effect of Finasteride - Prostate Cancer CTMS C3D Adopter Sites</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE GROUP_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812148 2812182 2812625</CsiPublicId>
            <CsiVersion>1.0 1.0 1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812149 2812625 2811715</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems Clinical Trial Mgmt Systems</PreferredName>
               <Version>1.0 1.0 1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Pancreatic Mucinous Neoplasms CTMS C3D Adopter Sites Duke University</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE GROUP_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812149 2812625 2811715</CsiPublicId>
            <CsiVersion>1.0 1.0 1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812151 2811715 2811954</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems CATEGORY</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Prostate - Lycopene Duke University Eligibility Criteria</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE CATEGORY_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812151 2811715 2811954</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812152 2812581 2811961</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems CATEGORY</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Barretts Esophagus - ASA-Esomeprazole DC_0205 Protocol/Admin.</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE CATEGORY_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812152 2812581 2811961</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812154 2812998 2811782</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Condition USAGE</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac Pioglitazone - Oral Leukoplakia CLINICAL TRIALS</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE USAGE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812154 2812998 2811782</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812155 2813054 2811831</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems CRF_DISEASE</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Sporadic Colorectal Neoplasia - Atrovastatin St. Joseph Hospital Breast</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812155 2813054 2811831</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812157 2813090 2811832</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems CRF_DISEASE</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Melanoma Pathobiology - Lovastatin SJO_ERCC1_07035 Lung</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812157 2813090 2811832</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812174 2957372 2811911</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Category CRF_DISEASE</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E - Hormone Receptor-Negative Breast Cancer Case Report Forms Version 3 Upper GI</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE Case Report Form DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812174 2957372 2811911</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812177 2931952 2811783</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Iloprost Trial TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Safety Study of Resiquimod for Atyical Nevi Iloprost 12079 ALL Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812177 2931952 2811783</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812182 2936518 2811784</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Condition TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Tissue Effect of Finasteride - Prostate Cancer Polyphenon E in Women w/ Modulation of Arachidonic Acid AML Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812182 2936518 2811784</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812183 3018781 2811786</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Condition TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Atrovastatin in Women at High Risk for Breast Cancer Metformin Colorectal Cancer APL Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812183 3018781 2811786</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812184 3081913 2811789</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition The Cancer Genome Atlas TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Spectral Markers in ASA Phase II Data Elements Adjuvant Esophageal</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE CATEGORY_TYPE1 TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812184 3081913 2811789</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812188 3110219 2811790</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Condition TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Se-Methyl-Seleno-L-Cystein (MSC) in Adult Men MSC and L SeMet in Adult Men Adjuvant Gastric</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812188 3110219 2811790</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812189 3114163 2811792</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Condition TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E - Pre-prostatectomy Prostate Cancer Cholecalciferol and Genistein Advanced Esophageal</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812189 3114163 2811792</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812190 2811957 2811793</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition CATEGORY TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Acolbifene - High Risk for Breast Cancer Labs Advanced Gastric</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE CATEGORY_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812190 2811957 2811793</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812194 2811962 2811795</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition CATEGORY TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>ALA PDT - Oral Leukoplakia Response CLL Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE CATEGORY_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812194 2811962 2811795</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812202 2811782 2811797</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition USAGE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>DIM - Prostate Cancer CLINICAL TRIALS CML Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE USAGE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812202 2811782 2811797</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812277 2811831 2811802</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition CRF_DISEASE TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Aminolevulinic Acid - Barrett's Esophagus Breast HCL Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812277 2811831 2811802</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812258 2811908 2811806</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition CRF_DISEASE TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Drug and Carcinogen Enzymes - Resveratrol Gynecologic MDS Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812258 2811908 2811806</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812539 2811832 2811810</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E - Bladder Cancer Lung NSCLC 2nd Line</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812539 2811832 2811810</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812551 2812550 2811811</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition KAI Research TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>9cUAB30 General CDEs NSCLC Advanced</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812551 2812550 2811811</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812553 3211760 2811817</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition KAI Research TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>EGF Receptor Signaling in ACF Pharmacokinetic Blood Sampling Primary Cervical</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812553 3211760 2811817</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812768 2811791 2811818</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>PK and Safety - Novel Retinoid (9cUAB30) Advanced Primary Endometrial</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812768 2811791 2811818</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812836 2811830 2811819</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Imiquimod for Atypical Nevi Recurr Gynecologic Primary Ovarian</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812836 2811830 2811819</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812843 2811871 2811821</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyethylene Glycol - Colon Carcinogenesis Colorectal SCLC 2nd Line</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812843 2811871 2811821</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812876 2811883 2811822</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Bronchial Dysplasia - Myo-Inositol Sarcoma SCLC Extensive</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812876 2811883 2811822</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812949 2811891 2811823</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Phase TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Exp. PK Formulations of SR13668 Phase II SCLC Limited</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE Phase Type TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812949 2811891 2811823</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812735 2811908 2811827</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>3, 3-Diindolylmethane Cervical Intraepithelial Gynecologic Unresect Pancreatic</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812735 2811908 2811827</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812736 2811909 2811829</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Transdermal 4-OHT vs oral TAM DCIS of the Breast Leukemia Resect Pancreatic</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812736 2811909 2811829</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812998 2811910 2811832</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE DISEASE</PreferredName>
               <Version>1.0 2.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Pioglitazone - Oral Leukoplakia Prostate Lung</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812998 2811910 2811832</CsiPublicId>
            <CsiVersion>1.0 2.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2813002 2811936 2811811</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition TTU CRF_TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Sulindac - Increased Risk of Melanoma Pathology Lung NSCLC Advanced</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2813002 2811936 2811811</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2813043 2811949 2811791</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE CRF_TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Ursodeoxycholic Acid - Barrett's Patients Brain Advanced</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2813043 2811949 2811791</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2813064 2812013 2811835</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition CRF_TTU DISEASE</PreferredName>
               <Version>1.0 2.31 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Erlotinib - Lesions of Lung Primary Brain New Melanoma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>Case Report Form TRIAL_TYPE_USAGE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2813064 2812013 2811835</CsiPublicId>
            <CsiVersion>1.0 2.31 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2957372 2811949 3298557</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Category CRF_DISEASE DISEASE</PreferredName>
               <Version>1.0 2.31 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Case Report Forms Version 3 Brain Hepatobiliary</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>Case Report Form DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2957372 2811949 3298557</CsiPublicId>
            <CsiVersion>1.0 2.31 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2842768 2811938 3298577</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Letrozole - Breast Cancer Recurrent Gyn Hepatobiliary</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2842768 2811938 3298577</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2859628 2811917 2811884</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Breast Sulindac DFMO Advanced Breast Adult STS New</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2859628 2811917 2811884</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2936518 2811819 2811885</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E in Women w/ Modulation of Arachidonic Acid Primary Ovarian Adult STS Recurrent</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2936518 2811819 2811885</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2979172 2812340 2811886</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Integrative Cancer Research TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>MyoInositol Chemoprevention in Colitis-Assoc. Dysplasia Dir Chall Lung Study Ped STS New</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE GROUP_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2979172 2812340 2811886</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3018781 2812349 2811883</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Demonstration Applications DISEASE</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Metformin Colorectal Cancer Rembrandt Sarcoma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE Case Report Form DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>3018781 2812349 2811883</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3018782 2812364 2811891</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition Condition Phase</PreferredName>
               <Version>1.0 1.0 1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Resveratrol in Postmenopausal Women Barretts Esophagus Phase II</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE Phase Type</ClassificationSchemeItemType>
            <CsiPublicId>3018782 2812364 2811891</CsiPublicId>
            <CsiVersion>1.0 1.0 1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3110219 2812391 2811890</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition CRF_TTU Phase</PreferredName>
               <Version>1.0 2.31 1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>MSC and L SeMet in Adult Men Treatment trials Phase III</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE Phase Type</ClassificationSchemeItemType>
            <CsiPublicId>3110219 2812391 2811890</CsiPublicId>
            <CsiVersion>1.0 2.31 1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3114163 2811889</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Cholecalciferol and Genistein Ped STS Recurrent</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>3114163 2811889</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3152820 2811904</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Pioglitazone - Lung Pre-Surgical NSCLC Multiple Myeloma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>3152820 2811904</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3182878 2811905</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Vitamin D - Bioactivity in the Skin Primary Amyloidosis</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>3182878 2811905</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3182879 2811906</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Metformin - Pre-Prostatectomy Prostate Cancer Waldenstrom Macrogl</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>3182879 2811906</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3211792 2811907</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Barrett's Esophagus Chemoprevention Metformin Bladder</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>3211792 2811907</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3528035 2811831</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Docosahexaenoic Acid Breast</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>3528035 2811831</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3293737 2811908</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>UAB30 in NMSC Gynecologic</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>3293737 2811908</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3303133 2811909</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Pomegranate - Prostate Cancer Leukemia</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>3303133 2811909</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811734 2811911</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Category DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Case Report Forms Upper GI</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>Case Report Form DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2811734 2811911</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812364 2811912</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Barretts Esophagus Head and Neck</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812364 2811912</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812377 2811913</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Bladder Cancer Lymphoma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812377 2811913</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812388 2811914</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Oral Leukoplakia Adjuvant Breast</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812388 2811914</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812399 2811917</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E for Cervical Ca Advanced Breast</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812399 2811917</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812415 2811919</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Sulindac for Breast Cancer Advanced Melanoma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812415 2811919</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812502 2811921</PublicId>
               <ContextName>DCP</ContextName>
               <ContextVersion>1.0</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Unconjugated Isoflavones in Women at High Risk for Breast Cancer ALL Relapse/Refract</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812502 2811921</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
      </CLASSIFICATIONSLIST>
      <ALTERNATENAMELIST>
         <ALTERNATENAMELIST_ITEM>
            <ContextName>DCP</ContextName>
            <ContextVersion>1.0</ContextVersion>
            <AlternateName>ENGLISH</AlternateName>
            <AlternateNameType>CONTEXT NAME</AlternateNameType>
            <Language>ENGLISH</Language>
         </ALTERNATENAMELIST_ITEM>
      </ALTERNATENAMELIST>
      <DATAELEMENTDERIVATION>
         <DerivationType>COMPOUND</DerivationType>
         <Methods/>
         <Rule>Combines Blood Pressure, Diastolic 2182885 with Alpha DVG BPD 2183222 that could be used for Oracle Clinical.</Rule>
         <ConcatenationCharacter/>
         <ComponentDataElementsList/>
      </DATAELEMENTDERIVATION>
   </DataElement>
   <DataElement num="2">
      <PUBLICID>64342</PUBLICID>
      <LONGNAME>Specimen Identifier Number</LONGNAME>
      <PREFERREDNAME>SPEC_ID_NUM</PREFERREDNAME>
      <PREFERREDDEFINITION>a unique identification number for the laboratory specimen submitted for analysis or bank storage.</PREFERREDDEFINITION>
      <VERSION>3.0</VERSION>
      <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
      <CONTEXTNAME>CTEP</CONTEXTNAME>
      <CONTEXTVERSION>2.31</CONTEXTVERSION>
      <ORIGIN>FALSE</ORIGIN>
      <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
      <DATAELEMENTCONCEPT>
         <PublicId>2013988</PublicId>
         <PreferredName>SPEC_ID</PreferredName>
         <PreferredDefinition>a unique identifier for the surgical pathology specimen.</PreferredDefinition>
         <LongName>Specimen Identifier</LongName>
         <Version>1.0</Version>
         <WorkflowStatus>RETIRED ARCHIVED</WorkflowStatus>
         <ContextName>CTEP</ContextName>
         <ContextVersion>2.31</ContextVersion>
         <ConceptualDomain>
            <PublicId>2008547</PublicId>
            <ContextName>CTEP</ContextName>
            <ContextVersion>2.31</ContextVersion>
            <PreferredName>SPEC_CHAR</PreferredName>
            <Version>1.0</Version>
            <LongName>Specimen Characteristics</LongName>
         </ConceptualDomain>
         <ObjectClass>
            <PublicId>0</PublicId>
            <ContextName>NCIP</ContextName>
            <ContextVersion>1.0</ContextVersion>
            <PreferredName>C19157</PreferredName>
            <Version>1.0</Version>
            <LongName>Specimen</LongName>
            <ConceptDetails>
               <ConceptDetails_ITEM>
                  <PREFERRED_NAME>C19157</PREFERRED_NAME>
                  <LONG_NAME>Specimen</LONG_NAME>
                  <CON_ID>2202566</CON_ID>
                  <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
                  <ORIGIN>NCI Thesaurus</ORIGIN>
                  <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
                  <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
                  <DISPLAY_ORDER>0</DISPLAY_ORDER>
               </ConceptDetails_ITEM>
            </ConceptDetails>
         </ObjectClass>
         <Property>
            <PublicId>0</PublicId>
            <ContextName>NCIP</ContextName>
            <ContextVersion>1.0</ContextVersion>
            <PreferredName>C25364</PreferredName>
            <Version>1.0</Version>
            <LongName>Identifier</LongName>
            <ConceptDetails>
               <ConceptDetails_ITEM>
                  <PREFERRED_NAME>C25364</PREFERRED_NAME>
                  <LONG_NAME>Identifier</LONG_NAME>
                  <CON_ID>2202473</CON_ID>
                  <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
                  <ORIGIN>NCI Thesaurus</ORIGIN>
                  <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
                  <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
                  <DISPLAY_ORDER>0</DISPLAY_ORDER>
               </ConceptDetails_ITEM>
            </ConceptDetails>
         </Property>
      </DATAELEMENTCONCEPT>
      <VALUEDOMAIN>
         <PublicId>2018646</PublicId>
         <PreferredName>Number</PreferredName>
         <PreferredDefinition>Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.</PreferredDefinition>
         <LongName>Specimen Identifier Number</LongName>
         <Version>1.1</Version>
         <WorkflowStatus>RELEASED</WorkflowStatus>
         <ContextName>CTEP</ContextName>
         <ContextVersion>1.1</ContextVersion>
         <ConceptualDomain>
            <PublicId>2202701</PublicId>
            <ContextName>NCIP</ContextName>
            <ContextVersion>1.0</ContextVersion>
            <PreferredName>C25337</PreferredName>
            <Version>1.0</Version>
            <LongName>Number</LongName>
         </ConceptualDomain>
         <Datatype>CHARACTER</Datatype>
         <MaximumLength>32</MaximumLength>
         <Representation>
            <PublicId>2184315</PublicId>
            <ContextName>C25337</ContextName>
            <ContextVersion>1.0</ContextVersion>
            <PreferredName>C25337</PreferredName>
            <Version>1.0</Version>
            <LongName>Number</LongName>
            <ConceptDetails>
               <ConceptDetails_ITEM>
                  <PREFERRED_NAME>C25337</PREFERRED_NAME>
                  <LONG_NAME>Number</LONG_NAME>
                  <CON_ID>2202701</CON_ID>
                  <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
                  <ORIGIN>NCI Thesaurus</ORIGIN>
                  <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
                  <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
                  <DISPLAY_ORDER>0</DISPLAY_ORDER>
               </ConceptDetails_ITEM>
            </ConceptDetails>
         </Representation>
         <PermissibleValues>
            <PermissibleValues_ITEM>
               <VALIDVALUE/>
               <VALUEMEANING/>
               <MEANINGDESCRIPTION/>
               <MEANINGCONCEPTS>FALSE</MEANINGCONCEPTS>
               <VMPUBLICID/>
               <VMVERSION/>
            </PermissibleValues_ITEM>
         </PermissibleValues>
         <ValueDomainConcepts/>
      </VALUEDOMAIN>
      <REFERENCEDOCUMENTSLIST>
         <REFERENCEDOCUMENTSLIST_ITEM>
            <Name>Specimen ID Number CRF Text DCP Document Text 2 CRF Text1 DCP Document Text CRF Text2</Name>
            <DocumentType>Preferred Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text</DocumentType>
            <DocumentText>Specimen ID Number Specimen ID Specimen Number Biopathology number Blood Specimen Number Surgical Pathology Number</DocumentText>
            <Language>ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH</Language>
            <DisplayOrder NULL="display-order">TRUE</DisplayOrder>
         </REFERENCEDOCUMENTSLIST_ITEM>
      </REFERENCEDOCUMENTSLIST>
      <CLASSIFICATIONSLIST>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812516 2812017 2812017</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE DISEASE</PreferredName>
               <Version>1.0 2.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Subclinical Neoplastic Lesions Phase II Lung Cancer Phase II Lung Cancer</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812516 2812017 2812017</CsiPublicId>
            <CsiVersion>1.0 2.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812102 2812151 2812245</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition DISEASE</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Budesonide Lung Nodules Prostate - Lycopene Phase II Breast Cancer</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812102 2812151 2812245</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812148 2812182 2812625</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition Clinical Trial Mgmt Systems</PreferredName>
               <Version>1.0 1.0 1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>SAMe - Hepatitis C cirrhosis Tissue Effect of Finasteride - Prostate Cancer CTMS C3D Adopter Sites</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE GROUP_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812148 2812182 2812625</CsiPublicId>
            <CsiVersion>1.0 1.0 1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812149 2812625 2811715</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems Clinical Trial Mgmt Systems</PreferredName>
               <Version>1.0 1.0 1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Pancreatic Mucinous Neoplasms CTMS C3D Adopter Sites Duke University</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE GROUP_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812149 2812625 2811715</CsiPublicId>
            <CsiVersion>1.0 1.0 1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812151 2811715 2811954</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems CATEGORY</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Prostate - Lycopene Duke University Eligibility Criteria</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE CATEGORY_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812151 2811715 2811954</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812152 2812581 2811961</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems CATEGORY</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Barretts Esophagus - ASA-Esomeprazole DC_0205 Protocol/Admin.</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE CATEGORY_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812152 2812581 2811961</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812154 2812998 2811782</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition USAGE</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac Pioglitazone - Oral Leukoplakia CLINICAL TRIALS</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE USAGE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812154 2812998 2811782</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812155 2813054 2811831</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems CRF_DISEASE</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Sporadic Colorectal Neoplasia - Atrovastatin St. Joseph Hospital Breast</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812155 2813054 2811831</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812157 2813090 2811832</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems CRF_DISEASE</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Melanoma Pathobiology - Lovastatin SJO_ERCC1_07035 Lung</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812157 2813090 2811832</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812174 2957372 2811911</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Category CRF_DISEASE</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E - Hormone Receptor-Negative Breast Cancer Case Report Forms Version 3 Upper GI</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE Case Report Form DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812174 2957372 2811911</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812177 2931952 2811783</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Iloprost Trial TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Safety Study of Resiquimod for Atyical Nevi Iloprost 12079 ALL Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812177 2931952 2811783</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812182 2936518 2811784</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Tissue Effect of Finasteride - Prostate Cancer Polyphenon E in Women w/ Modulation of Arachidonic Acid AML Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812182 2936518 2811784</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812183 3018781 2811786</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Atrovastatin in Women at High Risk for Breast Cancer Metformin Colorectal Cancer APL Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812183 3018781 2811786</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812184 3081913 2811789</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition The Cancer Genome Atlas TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Spectral Markers in ASA Phase II Data Elements Adjuvant Esophageal</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE CATEGORY_TYPE1 TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812184 3081913 2811789</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812188 3110219 2811790</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Se-Methyl-Seleno-L-Cystein (MSC) in Adult Men MSC and L SeMet in Adult Men Adjuvant Gastric</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812188 3110219 2811790</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812189 3114163 2811792</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E - Pre-prostatectomy Prostate Cancer Cholecalciferol and Genistein Advanced Esophageal</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812189 3114163 2811792</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812190 2811957 2811793</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CATEGORY TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Acolbifene - High Risk for Breast Cancer Labs Advanced Gastric</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE CATEGORY_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812190 2811957 2811793</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812194 2811962 2811795</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CATEGORY TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>ALA PDT - Oral Leukoplakia Response CLL Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE CATEGORY_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812194 2811962 2811795</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812202 2811782 2811797</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition USAGE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>DIM - Prostate Cancer CLINICAL TRIALS CML Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE USAGE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812202 2811782 2811797</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812277 2811831 2811802</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_DISEASE TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Aminolevulinic Acid - Barrett's Esophagus Breast HCL Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812277 2811831 2811802</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812258 2811908 2811806</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_DISEASE TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Drug and Carcinogen Enzymes - Resveratrol Gynecologic MDS Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812258 2811908 2811806</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812539 2811832 2811810</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E - Bladder Cancer Lung NSCLC 2nd Line</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812539 2811832 2811810</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812551 2812550 2811811</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition KAI Research TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>9cUAB30 General CDEs NSCLC Advanced</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812551 2812550 2811811</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812553 3211760 2811817</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition KAI Research TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>EGF Receptor Signaling in ACF Pharmacokinetic Blood Sampling Primary Cervical</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812553 3211760 2811817</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812768 2811791 2811818</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>PK and Safety - Novel Retinoid (9cUAB30) Advanced Primary Endometrial</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812768 2811791 2811818</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812836 2811830 2811819</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Imiquimod for Atypical Nevi Recurr Gynecologic Primary Ovarian</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812836 2811830 2811819</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812843 2811871 2811821</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyethylene Glycol - Colon Carcinogenesis Colorectal SCLC 2nd Line</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812843 2811871 2811821</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812876 2811883 2811822</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Bronchial Dysplasia - Myo-Inositol Sarcoma SCLC Extensive</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812876 2811883 2811822</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812949 2811891 2811823</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Phase TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Exp. PK Formulations of SR13668 Phase II SCLC Limited</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE Phase Type TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812949 2811891 2811823</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812735 2811908 2811827</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>3, 3-Diindolylmethane Cervical Intraepithelial Gynecologic Unresect Pancreatic</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812735 2811908 2811827</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812736 2811909 2811829</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Transdermal 4-OHT vs oral TAM DCIS of the Breast Leukemia Resect Pancreatic</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812736 2811909 2811829</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812998 2811910 2811832</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE DISEASE</PreferredName>
               <Version>1.0 2.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Pioglitazone - Oral Leukoplakia Prostate Lung</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812998 2811910 2811832</CsiPublicId>
            <CsiVersion>1.0 2.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2813002 2811936 2811811</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition TTU CRF_TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Sulindac - Increased Risk of Melanoma Pathology Lung NSCLC Advanced</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2813002 2811936 2811811</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2813043 2811949 2811791</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE CRF_TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Ursodeoxycholic Acid - Barrett's Patients Brain Advanced</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2813043 2811949 2811791</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2813064 2812013 2811835</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU DISEASE</PreferredName>
               <Version>1.0 2.31 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Erlotinib - Lesions of Lung Primary Brain New Melanoma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>Case Report Form TRIAL_TYPE_USAGE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2813064 2812013 2811835</CsiPublicId>
            <CsiVersion>1.0 2.31 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2957372 2811949 3298557</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Category CRF_DISEASE DISEASE</PreferredName>
               <Version>1.0 2.31 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Case Report Forms Version 3 Brain Hepatobiliary</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>Case Report Form DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2957372 2811949 3298557</CsiPublicId>
            <CsiVersion>1.0 2.31 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2842768 2811938 3298577</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Letrozole - Breast Cancer Recurrent Gyn Hepatobiliary</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2842768 2811938 3298577</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2859628 2811917 2811884</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Breast Sulindac DFMO Advanced Breast Adult STS New</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2859628 2811917 2811884</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2936518 2811819 2811885</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E in Women w/ Modulation of Arachidonic Acid Primary Ovarian Adult STS Recurrent</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2936518 2811819 2811885</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2979172 2812340 2811886</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Integrative Cancer Research TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>MyoInositol Chemoprevention in Colitis-Assoc. Dysplasia Dir Chall Lung Study Ped STS New</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE GROUP_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2979172 2812340 2811886</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3018781 2812349 2811883</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Demonstration Applications DISEASE</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Metformin Colorectal Cancer Rembrandt Sarcoma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE Case Report Form DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>3018781 2812349 2811883</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3018782 2812364 2811891</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition Phase</PreferredName>
               <Version>1.0 1.0 1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Resveratrol in Postmenopausal Women Barretts Esophagus Phase II</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE Phase Type</ClassificationSchemeItemType>
            <CsiPublicId>3018782 2812364 2811891</CsiPublicId>
            <CsiVersion>1.0 1.0 1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3110219 2812391 2811890</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU Phase</PreferredName>
               <Version>1.0 2.31 1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>MSC and L SeMet in Adult Men Treatment trials Phase III</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE Phase Type</ClassificationSchemeItemType>
            <CsiPublicId>3110219 2812391 2811890</CsiPublicId>
            <CsiVersion>1.0 2.31 1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
      </CLASSIFICATIONSLIST>
      <ALTERNATENAMELIST>
         <ALTERNATENAMELIST_ITEM>
            <ContextName>CTEP</ContextName>
            <ContextVersion>2.31</ContextVersion>
            <AlternateName>0064194 0064399 0064588 0065079 1745 64194 64399 64588 65079 SPEC_ID_NUM SPEC_ID_NUM DCP</AlternateName>
            <AlternateNameType>HISTORICAL_CDE_ID HISTORICAL_CDE_ID HISTORICAL_CDE_ID HISTORICAL_CDE_ID HISTORICAL_CDE_ID HISTORICAL_CDE_ID HISTORICAL_CDE_ID HISTORICAL_CDE_ID HISTORICAL_CDE_ID USED_BY USED_BY USED_BY</AlternateNameType>
            <Language>ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH</Language>
         </ALTERNATENAMELIST_ITEM>
      </ALTERNATENAMELIST>
      <DATAELEMENTDERIVATION>
         <DerivationType/>
         <Methods/>
         <Rule/>
         <ConcatenationCharacter/>
         <ComponentDataElementsList/>
      </DATAELEMENTDERIVATION>
   </DataElement>
   <DataElement num="3">
      <PUBLICID>58325</PUBLICID>
      <LONGNAME>Blood Tissue Specimen Other Diseases and Disorders Research Consent Ind-3</LONGNAME>
      <PREFERREDNAME>BL_TI_SPE_RSC_CON_IN</PREFERREDNAME>
      <PREFERREDDEFINITION>the yes/no/unknown indicator that asks whether the patient's blood or tissue may be kept for research about other health problems (e.g., causes of diabetes, Alzheimer's disease, and heart disease).</PREFERREDDEFINITION>
      <VERSION>3.0</VERSION>
      <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
      <CONTEXTNAME>CTEP</CONTEXTNAME>
      <CONTEXTVERSION>2.31</CONTEXTVERSION>
      <ORIGIN>FALSE</ORIGIN>
      <REGISTRATIONSTATUS/>
      <DATAELEMENTCONCEPT>
         <PublicId>2598150</PublicId>
         <PreferredName>BL_TI_SPE_O_DZ_RS_CO</PreferredName>
         <PreferredDefinition>information related to consent for the use of a blood or tissue specimen for research on other abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.</PreferredDefinition>
         <LongName>Blood Tissue Specimen Other Diseases and Disorders Research Consent</LongName>
         <Version>1.0</Version>
         <WorkflowStatus>RELEASED</WorkflowStatus>
         <ContextName>CTEP</ContextName>
         <ContextVersion>2.31</ContextVersion>
         <ConceptualDomain>
            <PublicId>2008530</PublicId>
            <ContextName>CTEP</ContextName>
            <ContextVersion>2.31</ContextVersion>
            <PreferredName>PT_CONSENT</PreferredName>
            <Version>1.0</Version>
            <LongName>Patient Consent</LongName>
         </ConceptualDomain>
         <ObjectClass>
            <PublicId>0</PublicId>
            <ContextName>NCIP NCIP NCIP</ContextName>
            <ContextVersion>1.0 1.0 1.0</ContextVersion>
            <PreferredName>C12434 C12801 C19157</PreferredName>
            <Version>1.0 1.0 1.0</Version>
            <LongName>Blood Tissue Specimen</LongName>
            <ConceptDetails>
               <ConceptDetails_ITEM>
                  <PREFERRED_NAME>C12434 C12801 C19157</PREFERRED_NAME>
                  <LONG_NAME>Blood Tissue Specimen</LONG_NAME>
                  <CON_ID>2202587 2202489 2202566</CON_ID>
                  <DEFINITION_SOURCE>NCI NCI NCI</DEFINITION_SOURCE>
                  <ORIGIN>NCI Thesaurus NCI Thesaurus NCI Thesaurus</ORIGIN>
                  <EVS_SOURCE>NCI_CONCEPT_CODE NCI_CONCEPT_CODE NCI_CONCEPT_CODE</EVS_SOURCE>
                  <PRIMARY_FLAG_IND>Yes Yes Yes</PRIMARY_FLAG_IND>
                  <DISPLAY_ORDER>2 1 0</DISPLAY_ORDER>
               </ConceptDetails_ITEM>
            </ConceptDetails>
         </ObjectClass>
         <Property>
            <PublicId>0</PublicId>
            <ContextName>NCIP NCIP NCIP NCIP</ContextName>
            <ContextVersion>1.0 1.0 1.0 1.0</ContextVersion>
            <PreferredName>C17649 C2991 C15319 C25460</PreferredName>
            <Version>1.0 1.0 1.0 1.0</Version>
            <LongName>Other Disease or Disorder Research Consent</LongName>
            <ConceptDetails>
               <ConceptDetails_ITEM>
                  <PREFERRED_NAME>C17649 C2991 C15319 C25460</PREFERRED_NAME>
                  <LONG_NAME>Other Disease or Disorder Research Consent</LONG_NAME>
                  <CON_ID>2202691 2202471 2202802 2203590</CON_ID>
                  <DEFINITION_SOURCE>NCI  NCI NCI NCI</DEFINITION_SOURCE>
                  <ORIGIN>NCI Thesaurus NCI Thesaurus NCI Thesaurus NCI Thesaurus</ORIGIN>
                  <EVS_SOURCE>NCI_CONCEPT_CODE NCI_CONCEPT_CODE NCI_CONCEPT_CODE NCI_CONCEPT_CODE</EVS_SOURCE>
                  <PRIMARY_FLAG_IND>Yes Yes Yes Yes</PRIMARY_FLAG_IND>
                  <DISPLAY_ORDER>3 2 1 0</DISPLAY_ORDER>
               </ConceptDetails_ITEM>
            </ConceptDetails>
         </Property>
      </DATAELEMENTCONCEPT>
      <VALUEDOMAIN>
         <PublicId>3506034</PublicId>
         <PreferredName>C38148</PreferredName>
         <PreferredDefinition>A response or indicator that can have a value of yes, no, or unknown.</PreferredDefinition>
         <LongName>Yes No Unknown Indicator</LongName>
         <Version>1.0</Version>
         <WorkflowStatus>RELEASED</WorkflowStatus>
         <ContextName>CTEP</ContextName>
         <ContextVersion>1.0</ContextVersion>
         <ConceptualDomain>
            <PublicId>2204653</PublicId>
            <ContextName>NCIP</ContextName>
            <ContextVersion>1.0</ContextVersion>
            <PreferredName>C38148</PreferredName>
            <Version>1.0</Version>
            <LongName>Yes, No, or Unknown Response</LongName>
         </ConceptualDomain>
         <Datatype>CHARACTER</Datatype>
         <MaximumLength>7</MaximumLength>
         <Representation>
            <PublicId>2548260</PublicId>
            <ContextName>C38148</ContextName>
            <ContextVersion>1.0</ContextVersion>
            <PreferredName>C38148</PreferredName>
            <Version>1.0</Version>
            <LongName>Ind-3</LongName>
            <ConceptDetails>
               <ConceptDetails_ITEM>
                  <PREFERRED_NAME>C38148</PREFERRED_NAME>
                  <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
                  <CON_ID>2204653</CON_ID>
                  <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
                  <ORIGIN>NCI Thesaurus</ORIGIN>
                  <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
                  <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
                  <DISPLAY_ORDER>0</DISPLAY_ORDER>
               </ConceptDetails_ITEM>
            </ConceptDetails>
         </Representation>
         <PermissibleValues>
            <PermissibleValues_ITEM>
               <VALIDVALUE>No Unknown Yes</VALIDVALUE>
               <VALUEMEANING>No Unknown Yes</VALUEMEANING>
               <MEANINGDESCRIPTION>The non-affirmative response to a question. Not known, not observed, not recorded, or refused. The affirmative response to a question or activity.</MEANINGDESCRIPTION>
               <MEANINGCONCEPTS>FALSE</MEANINGCONCEPTS>
               <VMPUBLICID>3197154 3241403 3197153</VMPUBLICID>
               <VMVERSION>1.0 1.0 1.0</VMVERSION>
            </PermissibleValues_ITEM>
         </PermissibleValues>
         <ValueDomainConcepts/>
      </VALUEDOMAIN>
      <REFERENCEDOCUMENTSLIST>
         <REFERENCEDOCUMENTSLIST_ITEM>
            <Name>Patient's Initial Consent giv CRF Text15 CRF Text2 CRF Text3 CRF Text5 CRF Text6 CRF Text8 CRF Text1 CRF Text4 CRF Text7 CRF Text9 CRF Text10 CRF Text11 CRF Text14 CRF Text12 CRF Text16 CRF Text13 CRF Text</Name>
            <DocumentType>Preferred Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text Alternate Question Text</DocumentType>
            <DocumentText>Patient's Initial Consent given for specimen use for research unrelated to the patient's cancer? My specimens may be kept for future use in research to learn about, prevent, or treat other health problems (for example: diabetes, Alzheimer's disease, and heart disease). Have you obtained the patient's consent for his or her tissue to be kept for use research about other health problems (for example: causes of diabetes, Alzheimer's disease, and heart disease)? Have you obtained the patient's consent to use his or her specimen(s) in future research about other health problems (for example: causes of diabetes, Alzheimer's disease, and heart disease)? Patient has given permission to keep sample(s) for use in future research to learn about, prevent, or treat other health problems (for example: diabetes, Alzheimer's disease, or heart disease) Patient has given permission to keep tissue sample(s) for use in future research to learn about, prevent, or treat other health problems (for example: diabetes, Alzheimer's disease, or heart disease) Patient has given permission to store and use his/her sample(s) for use in future research to learn about, prevent, or treat other health problems (for example: diabetes, Alzheimer's disease, or heart disease) Patient has given permission to keep blood and tissue specimens for use in future research to learn about, prevent or treat other health problems (for example: diabetes, Alzheimer's disease, or heart disease) Have you obtained the patient's consent for his or her tissue to be kept for use in research about other health problems (for example: causes of diabetes, Alzheimer's disease or heart disease) Did the patient consent to use of tissue and blood samples for research about other problems? Have you obtained the patient's consent for her tissue to be kept for use in research about other health problems (for example: causes of diabetes, Alzheimer's disease, and heart disease)? Patient has given permission to store and use his/her tissue samples for use in future research to learn about, prevent, or treat other health problems (for example: diabetes, Alzheimer's disease, or heart disease.) Have you obtained the patient's consent for his or her tissue to be kept for use in research about other health problems (for example: causes of diabetes, Alzheimer's disease and heart disease)? My specimens may be kept for research about other health problems (for example: causes of diabetes, Alzheimer's disease and heart disease). Patient has given permission for Alliance to store and use his/her tissue sample(s) for use in future research to learn about, prevent, or treat other health problems (for example: diabetes, Alzheimer's disease, or heart disease) Patient has given permission for NCCTG/Alliance to store and use his/her sample(s) for use in future research to learn about, prevent, or treat other health problems (for example: diabetes, Alzheimer's disease, or heart disease) Patient has given permission for Alliance/NCCTG to store and use his/her blood and tissue sample(s) for use in future research to learn about, prevent, or treat other health problems (for example: diabetes, Alzheimer's disease, or heart disease) Have you obtained the patient's consent for his or her tissue and blood to be kept for use in future research about other health problems (for example: causes of diabetes, Alzheimer's disease, and heart disease)?</DocumentText>
            <Language>ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH</Language>
            <DisplayOrder NULL="display-order">TRUE</DisplayOrder>
         </REFERENCEDOCUMENTSLIST_ITEM>
      </REFERENCEDOCUMENTSLIST>
      <CLASSIFICATIONSLIST>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812516 2812017 2812017</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE DISEASE</PreferredName>
               <Version>1.0 2.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Subclinical Neoplastic Lesions Phase II Lung Cancer Phase II Lung Cancer</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812516 2812017 2812017</CsiPublicId>
            <CsiVersion>1.0 2.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812102 2812151 2812245</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition DISEASE</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Budesonide Lung Nodules Prostate - Lycopene Phase II Breast Cancer</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812102 2812151 2812245</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812148 2812182 2812625</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition Clinical Trial Mgmt Systems</PreferredName>
               <Version>1.0 1.0 1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>SAMe - Hepatitis C cirrhosis Tissue Effect of Finasteride - Prostate Cancer CTMS C3D Adopter Sites</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE GROUP_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812148 2812182 2812625</CsiPublicId>
            <CsiVersion>1.0 1.0 1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812149 2812625 2811715</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems Clinical Trial Mgmt Systems</PreferredName>
               <Version>1.0 1.0 1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Pancreatic Mucinous Neoplasms CTMS C3D Adopter Sites Duke University</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE GROUP_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812149 2812625 2811715</CsiPublicId>
            <CsiVersion>1.0 1.0 1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812151 2811715 2811954</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems CATEGORY</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Prostate - Lycopene Duke University Eligibility Criteria</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE CATEGORY_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812151 2811715 2811954</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812152 2812581 2811961</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems CATEGORY</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Barretts Esophagus - ASA-Esomeprazole DC_0205 Protocol/Admin.</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE CATEGORY_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812152 2812581 2811961</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812154 2812998 2811782</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition USAGE</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac Pioglitazone - Oral Leukoplakia CLINICAL TRIALS</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE USAGE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812154 2812998 2811782</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812155 2813054 2811831</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems CRF_DISEASE</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Sporadic Colorectal Neoplasia - Atrovastatin St. Joseph Hospital Breast</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812155 2813054 2811831</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812157 2813090 2811832</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Clinical Trial Mgmt Systems CRF_DISEASE</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Melanoma Pathobiology - Lovastatin SJO_ERCC1_07035 Lung</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812157 2813090 2811832</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812174 2957372 2811911</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Category CRF_DISEASE</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E - Hormone Receptor-Negative Breast Cancer Case Report Forms Version 3 Upper GI</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE Case Report Form DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812174 2957372 2811911</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812177 2931952 2811783</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Iloprost Trial TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Safety Study of Resiquimod for Atyical Nevi Iloprost 12079 ALL Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812177 2931952 2811783</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812182 2936518 2811784</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Tissue Effect of Finasteride - Prostate Cancer Polyphenon E in Women w/ Modulation of Arachidonic Acid AML Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812182 2936518 2811784</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812183 3018781 2811786</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Atrovastatin in Women at High Risk for Breast Cancer Metformin Colorectal Cancer APL Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812183 3018781 2811786</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812184 3081913 2811789</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition The Cancer Genome Atlas TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Spectral Markers in ASA Phase II Data Elements Adjuvant Esophageal</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE CATEGORY_TYPE1 TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812184 3081913 2811789</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812188 3110219 2811790</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Se-Methyl-Seleno-L-Cystein (MSC) in Adult Men MSC and L SeMet in Adult Men Adjuvant Gastric</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812188 3110219 2811790</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812189 3114163 2811792</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E - Pre-prostatectomy Prostate Cancer Cholecalciferol and Genistein Advanced Esophageal</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812189 3114163 2811792</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812190 2811957 2811793</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CATEGORY TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Acolbifene - High Risk for Breast Cancer Labs Advanced Gastric</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE CATEGORY_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812190 2811957 2811793</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812194 2811962 2811795</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CATEGORY TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>ALA PDT - Oral Leukoplakia Response CLL Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE CATEGORY_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812194 2811962 2811795</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812202 2811782 2811797</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition USAGE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>DIM - Prostate Cancer CLINICAL TRIALS CML Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE USAGE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812202 2811782 2811797</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812277 2811831 2811802</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_DISEASE TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Aminolevulinic Acid - Barrett's Esophagus Breast HCL Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812277 2811831 2811802</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812258 2811908 2811806</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_DISEASE TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Drug and Carcinogen Enzymes - Resveratrol Gynecologic MDS Prev Untreated</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812258 2811908 2811806</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812539 2811832 2811810</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E - Bladder Cancer Lung NSCLC 2nd Line</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812539 2811832 2811810</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812551 2812550 2811811</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition KAI Research TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>9cUAB30 General CDEs NSCLC Advanced</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812551 2812550 2811811</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812553 3211760 2811817</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition KAI Research TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>EGF Receptor Signaling in ACF Pharmacokinetic Blood Sampling Primary Cervical</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE GROUP_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812553 3211760 2811817</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812768 2811791 2811818</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>PK and Safety - Novel Retinoid (9cUAB30) Advanced Primary Endometrial</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812768 2811791 2811818</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812836 2811830 2811819</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Imiquimod for Atypical Nevi Recurr Gynecologic Primary Ovarian</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812836 2811830 2811819</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812843 2811871 2811821</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyethylene Glycol - Colon Carcinogenesis Colorectal SCLC 2nd Line</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812843 2811871 2811821</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812876 2811883 2811822</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Bronchial Dysplasia - Myo-Inositol Sarcoma SCLC Extensive</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812876 2811883 2811822</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812949 2811891 2811823</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Phase TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Exp. PK Formulations of SR13668 Phase II SCLC Limited</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE Phase Type TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812949 2811891 2811823</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812735 2811908 2811827</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>3, 3-Diindolylmethane Cervical Intraepithelial Gynecologic Unresect Pancreatic</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812735 2811908 2811827</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812736 2811909 2811829</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Transdermal 4-OHT vs oral TAM DCIS of the Breast Leukemia Resect Pancreatic</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812736 2811909 2811829</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812998 2811910 2811832</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE DISEASE</PreferredName>
               <Version>1.0 2.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Pioglitazone - Oral Leukoplakia Prostate Lung</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812998 2811910 2811832</CsiPublicId>
            <CsiVersion>1.0 2.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2813002 2811936 2811811</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition TTU CRF_TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Sulindac - Increased Risk of Melanoma Pathology Lung NSCLC Advanced</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2813002 2811936 2811811</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2813043 2811949 2811791</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE CRF_TTU</PreferredName>
               <Version>1.0 2.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Ursodeoxycholic Acid - Barrett's Patients Brain Advanced</ClassificationSchemeItemName>
            ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2813043 2811949 2811791</CsiPublicId>
            <CsiVersion>1.0 2.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2813064 2812013 2811835</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU DISEASE</PreferredName>
               <Version>1.0 2.31 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Erlotinib - Lesions of Lung Primary Brain New Melanoma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>Case Report Form TRIAL_TYPE_USAGE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2813064 2812013 2811835</CsiPublicId>
            <CsiVersion>1.0 2.31 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2957372 2811949 3298557</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Category CRF_DISEASE DISEASE</PreferredName>
               <Version>1.0 2.31 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Case Report Forms Version 3 Brain Hepatobiliary</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>Case Report Form DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2957372 2811949 3298557</CsiPublicId>
            <CsiVersion>1.0 2.31 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2842768 2811938 3298577</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Letrozole - Breast Cancer Recurrent Gyn Hepatobiliary</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2842768 2811938 3298577</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2859628 2811917 2811884</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Breast Sulindac DFMO Advanced Breast Adult STS New</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2859628 2811917 2811884</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2936518 2811819 2811885</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU TTU</PreferredName>
               <Version>1.0 2.31 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E in Women w/ Modulation of Arachidonic Acid Primary Ovarian Adult STS Recurrent</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2936518 2811819 2811885</CsiPublicId>
            <CsiVersion>1.0 2.31 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2979172 2812340 2811886</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Integrative Cancer Research TTU</PreferredName>
               <Version>1.0 1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>MyoInositol Chemoprevention in Colitis-Assoc. Dysplasia Dir Chall Lung Study Ped STS New</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE GROUP_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2979172 2812340 2811886</CsiPublicId>
            <CsiVersion>1.0 1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3018781 2812349 2811883</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Demonstration Applications DISEASE</PreferredName>
               <Version>1.0 1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Metformin Colorectal Cancer Rembrandt Sarcoma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE Case Report Form DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>3018781 2812349 2811883</CsiPublicId>
            <CsiVersion>1.0 1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3018782 2812364 2811891</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition Condition Phase</PreferredName>
               <Version>1.0 1.0 1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Resveratrol in Postmenopausal Women Barretts Esophagus Phase II</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE Phase Type</ClassificationSchemeItemType>
            <CsiPublicId>3018782 2812364 2811891</CsiPublicId>
            <CsiVersion>1.0 1.0 1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3110219 2812391 2811890</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition CRF_TTU Phase</PreferredName>
               <Version>1.0 2.31 1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>MSC and L SeMet in Adult Men Treatment trials Phase III</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE Phase Type</ClassificationSchemeItemType>
            <CsiPublicId>3110219 2812391 2811890</CsiPublicId>
            <CsiVersion>1.0 2.31 1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3114163 2811889</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Cholecalciferol and Genistein Ped STS Recurrent</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>3114163 2811889</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3152820 2811904</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Pioglitazone - Lung Pre-Surgical NSCLC Multiple Myeloma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>3152820 2811904</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3182878 2811905</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Vitamin D - Bioactivity in the Skin Primary Amyloidosis</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>3182878 2811905</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3182879 2811906</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Metformin - Pre-Prostatectomy Prostate Cancer Waldenstrom Macrogl</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>3182879 2811906</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3211792 2811907</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Barrett's Esophagus Chemoprevention Metformin Bladder</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>3211792 2811907</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3528035 2811831</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Docosahexaenoic Acid Breast</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>3528035 2811831</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3293737 2811908</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>UAB30 in NMSC Gynecologic</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>3293737 2811908</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>3303133 2811909</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Pomegranate - Prostate Cancer Leukemia</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>3303133 2811909</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811734 2811911</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Category DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Case Report Forms Upper GI</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>Case Report Form DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2811734 2811911</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812364 2811912</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Barretts Esophagus Head and Neck</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812364 2811912</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812377 2811913</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition DISEASE</PreferredName>
               <Version>1.0 2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Bladder Cancer Lymphoma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812377 2811913</CsiPublicId>
            <CsiVersion>1.0 2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812388 2811914</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Oral Leukoplakia Adjuvant Breast</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812388 2811914</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812399 2811917</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Polyphenon E for Cervical Ca Advanced Breast</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812399 2811917</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812415 2811919</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Sulindac for Breast Cancer Advanced Melanoma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812415 2811919</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812502 2811921</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>Condition TTU</PreferredName>
               <Version>1.0 2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Unconjugated Isoflavones in Women at High Risk for Breast Cancer ALL Relapse/Refract</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812502 2811921</CsiPublicId>
            <CsiVersion>1.0 2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811922</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>AML Relapse/Refract</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811922</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811923</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>APL Relapse/Refract</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811923</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811924</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>CLL Relapse/Refract</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811924</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811925</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>CML Relapse/Refract</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811925</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811926</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>HCL Relapse/Refract</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811926</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811927</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Local-Reg Melanoma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811927</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811928</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>MDS Relapse/Refract</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811928</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811931</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811931</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811938</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Recurrent Gyn</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811938</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811940</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Bone Sarcoma New</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811940</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811941</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Bone Sarcoma Recur</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811941</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811942</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Curative Head/Neck</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811942</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811943</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Hodgkin's Lymphoma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811943</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811944</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>NonHodgkins Lymphoma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811944</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811945</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Palliative Head/Neck</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811945</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811949</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>DISEASE</PreferredName>
               <Version>2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2811949</CsiPublicId>
            <CsiVersion>2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811950</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>DISEASE</PreferredName>
               <Version>2.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2811950</CsiPublicId>
            <CsiVersion>2.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812014</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Primary Brain Recurr</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812014</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812013</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812013</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812015</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Metastatic Brain</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2812015</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811673</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>CCR Implementation</PreferredName>
               <Version>1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2811673</CsiPublicId>
            <CsiVersion>1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811914</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>CRF_TTU</PreferredName>
               <Version>2.31</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811914</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2811931</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>CRF_TTU</PreferredName>
               <Version>2.31</Version>
            ClassificationScheme>
            <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
            <CsiPublicId>2811931</CsiPublicId>
            <CsiVersion>2.31</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812367</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>C3D Domain</PreferredName>
               <Version>1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812367</CsiPublicId>
            <CsiVersion>1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
         <CLASSIFICATIONSLIST_ITEM>
            <ClassificationScheme>
               <PublicId>2812486</PublicId>
               <ContextName>CTEP</ContextName>
               <ContextVersion>2.31</ContextVersion>
               <PreferredName>In-class Examples</PreferredName>
               <Version>1.0</Version>
            </ClassificationScheme>
            <ClassificationSchemeItemName>Short Examples</ClassificationSchemeItemName>
            <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
            <CsiPublicId>2812486</CsiPublicId>
            <CsiVersion>1.0</CsiVersion>
         </CLASSIFICATIONSLIST_ITEM>
      </CLASSIFICATIONSLIST>
      <ALTERNATENAMELIST>
         <ALTERNATENAMELIST_ITEM>
            <ContextName>CTEP</ContextName>
            <ContextVersion>2.31</ContextVersion>
            <AlternateName>0061371 0062876 0064919 0065468 caBIG</AlternateName>
            <AlternateNameType>HISTORICAL_CDE_ID HISTORICAL_CDE_ID HISTORICAL_CDE_ID HISTORICAL_CDE_ID USED_BY</AlternateNameType>
            <Language>ENGLISH ENGLISH ENGLISH ENGLISH ENGLISH</Language>
         </ALTERNATENAMELIST_ITEM>
      </ALTERNATENAMELIST>
      <DATAELEMENTDERIVATION>
         <DerivationType/>
         <Methods/>
         <Rule/>
         <ConcatenationCharacter/>
         <ComponentDataElementsList/>
      </DATAELEMENTDERIVATION>
   </DataElement>
</DataElementsList>
